Why It Matters
The Academy of Managed Care Pharmacy (AMCP) is lobbying on the Access to PDTs Act, a House bill that had not advanced beyond committee referral as of Nov. 4, 2026.
Prescription digital therapeutics are software treatments reviewed by the Food and Drug Administration and prescribed to patients. The bill concerns Medicare and Medicaid coverage of them, the topic the filing lists.
By the Numbers
AMCP's in-house third-quarter report lists $180,000, down $140,000 from the second quarter and down $20,000 from the third quarter of 2025. The report was signed Nov. 4, after the Oct. 20 deadline.
The client also has a Tiber Creek Group Inc. report of $80,000 for the quarter. That brings the client total to $260,000, down $140,000 from the second quarter and down $20,000 from a year earlier.
Four in-house lobbyists are named:
- Adam Colborn, vice president, government affairs
- Tyler Thorne, manager, government affairs. He served as an intern in the office of Rep. Jimmy Gomez (D-CA) in 2019.
- Geni Tunstall, associate vice president, regulatory affairs
- Tom Casey, associate director, government affairs
Broader Context
H.R. 3288 was introduced May 8, 2025, by Rep. Kevin Hern (R-OK), with Rep. Mike Thompson (D-CA) among its original cosponsors. It sits in the House Energy and Commerce Committee. Rep. Deborah Ross was added as a cosponsor on Dec. 9, 2025.
The Senate companion, S. 1702, came from Sen. Shelley Moore Capito (R-WV), with Sen. Jeanne Shaheen (D-NH) among its original cosponsors. It sits in the Senate Finance Committee and lists four Senate cosponsors.
AMCP backed the bill, saying coverage could expand access to prescribed software treatments. ATA Action, the American Telemedicine Association's advocacy arm, also supported it, arguing that coverage and reimbursement codes could address gaps in care.
Digital psychiatry researcher John Torous called reimbursement premature in December 2022. He said there was no evidence it would increase access to high-quality care, and warned it could shift costs to patients.
The Bottom Line
Watch whether the House Energy and Commerce Committee or the Senate Finance Committee acts on the bill. Neither has a scheduled step in the research.
In AMCP's lobbying operation, the clearest change across complete quarters is the departure of one lobbyist after the first quarter of 2026, leaving a four-person team.
Access the Legis1 platform for comprehensive political news, data, and insights
Spot something wrong? Report an issue with this article
